Published in final edited form as:

Contemp Clin Trials. 2020 November ; 98: 106168. doi:10.1016/j.cct.2020.106168.

Protocol of a Randomized Trial of Acceptance and Commitment Therapy for Fatigue Interference in Metastatic Breast Cancer

Catherine E. Mosher, Ph.D.^{a,*}, Ellen Krueger, M.S.^a, Adam T. Hirsh, Ph.D.^a, Kathy D. Miller, M.D.^b, Tarah J. Ballinger, M.D.^b, Anna Maria Storniolo, M.D.^b, Bryan P. Schneider, M.D.^b, Erin V. Newton, M.D.^b, Victoria L. Champion, Ph.D., RN, FAAN^c, Shelley A. Johns, Psy.D., ABPP^d

^aDepartment of Psychology, Indiana University-Purdue University Indianapolis, 402 North Blackford Street, LD 124, Indianapolis, IN 46202, USA

^bIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana Cancer Pavilion, 535 Barnhill Drive, Suite 473, Indianapolis, IN 46202, USA

^cIndiana University School of Nursing, 1111 Middle Drive, NU 340G, Indianapolis, IN 46202, USA

^dIndiana University School of Medicine, Center for Health Services Research, Regenstrief Institute, 1101 W. 10th Street, Indianapolis, IN 46202, USA.

Abstract

Fatigue interference with activities, mood, and cognition is one of the most prevalent and distressing concerns of metastatic breast cancer patients. To date, there are no evidence-based interventions for reducing fatigue interference in metastatic breast cancer and other advanced cancer populations. In pilot studies, Acceptance and Commitment Therapy (ACT) has shown potential for reducing symptom-related suffering in cancer patients. The current Phase II trial seeks to more definitively examine the efficacy of telephone-based ACT for women with metastatic breast cancer who are experiencing fatigue interference. In this trial, 250 women are randomly assigned to either the ACT intervention or an education/support control condition. Women in both conditions attend six weekly 50-minute telephone sessions. The primary aim of this study is to test the effect of telephone-based ACT on fatigue interference. Secondary outcomes include sleep interference, engagement in daily activities, and quality of life. Outcomes are assessed at baseline, 2 weeks post-intervention, and 3 and 6 months post-intervention. This trial also examines whether increases in psychological flexibility, defined as full awareness of the present moment while persisting in behaviors aligned with personal values, account for the beneficial effect of ACT on fatigue interference. After demonstrating ACT's efficacy, the intervention can be widely disseminated to clinicians who care for metastatic breast cancer patients. Our findings will also inform future ACT trials with various cancer populations and functional outcomes.

*Correspondence to: Catherine E. Mosher, Ph.D., Department of Psychology, Indiana University-Purdue University Indianapolis, 402 North Blackford Street, LD 124, Indianapolis, IN 46202, USA., cemosher@iupui.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Acceptance and Commitment Therapy; fatigue; sleep; metastatic breast cancer; psychosocial intervention; symptom management

1. Introduction

Fatigue is a prevalent, persistent, debilitating symptom in metastatic breast cancer (MBC) patients [1–3]. Moderate-to-severe fatigue is reported by over 50% of MBC patients [1, 2]. Fatigue frequently co-occurs with a number of symptoms, such as sleep disturbance, cognitive concerns, anxiety, and depressive symptoms [4, 5], resulting in impaired daily activities [1, 5, 6]. Evidence-based interventions for managing fatigue in MBC and other advanced cancer populations are lacking [7–9]. A Cochrane meta-analysis of pharmacologic interventions for fatigue in advanced cancer and other palliative care patients characterized the evidence as inconclusive and highlighted the small, heterogeneous samples in many studies [7]. Furthermore, of the five psychotherapy trials for MBC patients targeting fatigue [9], only a trial of year-long supportive-expressive group therapy effectively reduced fatigue [10]; importantly, this finding was not replicated by others [11]. Innovative approaches are therefore needed to reduce fatigue-related suffering and interference with functioning.

One behavioral intervention that shows potential for reducing symptom-related suffering in cancer patients is Acceptance and Commitment Therapy (ACT) [12, 13]. Rather than focusing on symptom reduction, the goal of ACT is to increase psychological flexibility so that difficult internal experiences (e.g., physical symptoms, feelings, thoughts) interfere less with meaningful activities [14, 15]. Psychological flexibility is comprised of mindfulness/acceptance processes (i.e., nonjudgmental attention to the present moment) and commitment/behavior change processes (i.e., identifying personal values such as family or work and taking action steps consistent with these values) [15]. ACT has been shown to reduce distress and pain interference in patients with chronic pain [16–19] and has been tested in pilot trials with cancer patients [13, 14, 20–22]. In our pilot RCT, MBC patients were randomized to six telephone sessions of either ACT or time-equivalent education/support [23]. ACT showed strong evidence of feasibility and promise with respect to fatigue and sleep interference with activities, mood, and cognition. Feasibility was demonstrated by the eligibility screening rate (64% of reached patients agreed to be screened) and the retention rate (83% [39/47] at 8 weeks post-intervention).

The primary aim of this NIH-funded Phase II RCT is to more definitively examine the efficacy of our telephone-based ACT intervention for women with MBC who have fatigue interference. We hypothesize that ACT will lead to an improved primary outcome of fatigue interference as compared to time-equivalent education/support. Our second aim is to test the effects of telephone-based ACT on the secondary outcomes of sleep interference, engagement in daily activities, and quality of life. We hypothesize that ACT will lead to superior secondary outcomes relative to education/support. Our third aim is to test the hypothesis that increased psychological flexibility will mediate ACT's effect on fatigue interference. Our fourth aim is to explore changes in the two core aspects of psychological

flexibility (i.e., mindfulness/acceptance and commitment/behavior change processes) as mediators of ACT's effect on fatigue interference. The current paper describes the rationale, design, methods, and statistical plan for this RCT that aims to address a critical gap in comprehensive, evidence-based care for women with MBC.

2. Materials and Methods

2.1. Overview of study design

This Phase II RCT tests the effects of telephone-based ACT on fatigue interference and related outcomes in women with MBC. Our recruitment goal is 250 patients with moderate-to-severe fatigue interference. We recruited about six patients per month over 8 months in our pilot [23]. Assuming a similar recruitment rate, we will recruit 250 patients over 3.5 years. Patients are randomized to six weekly 50-minute telephone sessions of ACT or six weekly 50-minute telephone sessions of education/support. Outcomes are assessed at baseline, 2 weeks post-intervention (primary endpoint), and 3 and 6 months post-intervention. This trial was registered in [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03998618) (NCT03998618) and approved by the Indiana University Institutional Review Board.

2.2. Participant eligibility criteria

Eligible patients meet the following inclusion criteria: a) 18 years old, b) at least 3 weeks post-diagnosis of Stage IV breast cancer as ascertained through medical records and consultation with the attending oncologist, and c) moderate to severe fatigue interference (i.e., mean score ≥ 2.5 on the Fatigue Interference subscale of the Fatigue Symptom Inventory [FSI]) [24, 25]. The clinical validity of this cut point is supported by our pilot research with MBC patients. Exclusion criteria include: a) significant cognitive impairment (dementia/delirium, psychosis) as ascertained by a medical record review and administration of a mental status questionnaire [26], b) patient-reported Eastern Cooperative Oncology Group (ECOG) score > 2 (spend most of the day in bed or chair) [27], c) enrolled in hospice, d) lack of English fluency, e) male, and f) no working phone service. Those with an ECOG score above 2 are excluded, as the ACT intervention is designed for those who can engage in at least moderate levels of activity.

2.3. Recruitment

Under an IRB-approved waiver of HIPAA authorization, study staff search electronic health records for patients with a diagnosis of MBC, along with the name of their primary oncologist. The primary oncologist reviews patient lists and indicates those whom we may contact about participation. Potentially eligible women are mailed a study introductory letter along with a consent form. The letter includes a phone number for those who have questions or wish to opt out of further contact from the study team.

A research assistant (RA) calls all patients who do not opt out approximately 1 to 2 weeks after the letter is mailed. The RA describes the study as outlined in the consent form, answers questions, and administers a screening assessment (i.e., Fatigue Interference subscale of FSI [24, 25], ECOG [27], and mental status questionnaire [26]) with the

patient's permission. Eligible and interested patients provide consent for study participation over the phone under a waiver of documentation of written informed consent.

2.4. Randomization and blinding

Following baseline assessments, patients are randomly assigned to ACT or education/support using stratified block randomization to balance the groups by age (<65 yrs. vs. 65 yrs.) and performance status (patient-reported ECOG scores 0 or 1 vs. 2 [27]). We are stratifying randomization by performance status because it is a key factor in MBC treatment decisions [28]. The statistician uses the R package “blockrand” [29, 30] to generate random assignments within blocks. Randomly varying block sizes of 2, 4, 6, and 8 are used to maintain allocation concealment and assure balanced allocation to study conditions. Following randomization, intervention assignments are identifiable to patients, interventionists, and staff mailing intervention materials. Other investigators, data monitoring committee members, outcome assessors, and data analysts are blinded throughout the trial.

2.5. Interventions

2.5.1. Acceptance and Commitment Therapy (ACT)—Study team members developed the ACT manual, which was informed by literature on fatigue and related symptoms in MBC patients [1, 2, 4], the ACT model [12, 15], previous ACT trials with patients with cancer and other chronic conditions [14, 17, 18, 20, 31, 32], and our clinical experience. Table 1 provides a summary of the intervention components. Grounded in the ACT model [15], the intervention is designed to reduce fatigue interference by increasing psychological flexibility, consisting of mindfulness/acceptance processes and commitment/behavior change processes (see Figure 1: Conceptual Model). The mindfulness/acceptance component of psychological flexibility is targeted through mindfulness practices that facilitate non-reactive acceptance of fatigue-related thoughts, emotions, and bodily sensations. Willingness to experience the present moment courageously and flexibly is emphasized. Additionally, the commitment/behavior change component of psychological flexibility is targeted through identifying deeply held values (e.g., being a loving, engaged parent) and making behavior changes consistent with these values. Weekly value-based action goals are in the SMART format (Specific, Measurable, Achievable, Relevant, and Time-Bound). Thus, ACT emphasizes living consistently with one's values even when fatigued rather than focusing one's cognitive and physical energies on controlling fatigue. Although all patients learn the same set of skills, sessions are tailored to their unique cancer experience and other challenges. The therapist administers three items from the Fatigue Symptom Inventory (i.e., average fatigue and fatigue interference with general activity and enjoyment of life) [24, 25], two PROMIS anxiety items [33], and two PROMIS depression items [33] during each session. These reports allow the therapist to monitor fatigue and distress. The therapist also assesses and records the patient's home practice of mindfulness and other skills and ends with a discussion of practice for the week ahead. Handouts summarizing the topics of each session and recordings that our team developed to guide mindfulness practices are sent to patients.

2.5.2. Education/Support—The education/support condition was tested in our pilot feasibility trial [23] and is similar to controls in other cancer trials [34, 35]. Patients randomized to this condition discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist directs patients to resources for practical and health information and contact information for psychosocial services. Additionally, the same fatigue, depression, and anxiety assessments as those in the ACT condition are completed during each session [24, 25, 33]. Table 1 provides a summary of the education/support components. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns and symptoms experienced by cancer patients, and an overview of medical center and community resources for addressing these concerns. Therapists also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Education/support patients receive handouts summarizing the topics of each session and are asked to review them as homework. ACT concepts are not discussed.

2.5.3. Intervention training and supervision—Therapists are doctoral level psychologists or advanced doctoral students in clinical psychology with extensive training and experience delivering ACT or supportive counseling. Different therapists deliver each intervention to prevent cross-contamination between study conditions. Therapists received initial education in MBC diagnosis and treatment, psychological distress, and either ACT or supportive counseling techniques with training protocols developed in previous studies. Initial training also included role-plays of sessions detailed in manuals. All sessions are digitally recorded, and licensed psychologists and advanced doctoral students in clinical psychology randomly select recordings to review for adherence to the manual using checklists developed in our pilot work. Individuals monitoring adherence have expertise in ACT or supportive counseling techniques and received training in fidelity monitoring. During regular supervision with therapists, treatment adherence scores (number of required topics and exercises covered in each session/total number of fidelity criteria) are provided and treatment fidelity issues are discussed. Therapists implement the feedback in subsequent sessions.

2.6. Retention

A number of strategies are used to increase study retention. All study staff, including RAs and therapists, have been trained to clearly communicate expectations to patients and to offer the option of completing follow-ups if they do not adhere to the intervention. Use of the telephone for all assessments and the intervention reduces barriers to participation for rural residents and those with low incomes. Text, phone, or email reminders are sent to patients prior to appointments. Patients receive \$40 in gift cards to a major retailer for participating in each of the four assessments, for a possible total of \$160 in gift cards.

2.7. Study measures and data collection schedule

Study measures and the data collection schedule are found in Table 2. Measures equate to a 35-minute baseline assessment and three, 30-minute follow-up assessments conducted by

research assistants blind to study condition. All measures have evidence of reliability and validity in cancer patients.

2.7.1. Primary outcome: fatigue interference—The primary outcome measure is the 7-item Fatigue Interference subscale of the FSI [24, 25]. Items are rated on 11-point scales (0 = *no interference*; 10 = *extreme interference*) that assess the extent to which fatigue in the past week interfered with general level of activity, ability to bathe and dress, normal work activity (including housework), ability to concentrate, relations with others, enjoyment of life, and mood.

2.7.2. Secondary outcomes—*Sleep interference* is assessed with the 8-item Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment measure [36, 37]. This measure evaluates the perceived interference of sleep problems with activities, mood, and cognition. *Engagement in daily activities* is assessed with the 6-item PROMIS short-form measure of ability to participate in social roles and activities [38]. The items, which are reverse-coded, measure difficulty engaging in social and recreational activities as well as usual work (including housework). *Quality of life* is measured with the 27-item Functional Assessment of Cancer Therapy-General (FACT-G), consisting of four subscales: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being [39]. An overall score is computed to represent general quality of life.

2.7.3. Mediators—*Psychological flexibility*, as measured by the 7-item Acceptance and Action Questionnaire-II (AAQ-II) [40], is assessed as a hypothesized mediator of the intervention's effect on fatigue interference. The two core components of psychological flexibility are also assessed as exploratory mediators. First, *mindfulness/acceptance* is measured by the 10-item Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) [41]. The scale provides a comprehensive assessment of mindfulness processes, including attention, present-focus, awareness, and acceptance/non-judgement. Second, *commitment/behavior change* is measured by the 5-item Value Progress subscale of the Valuing Questionnaire [42]. This subscale assesses progress in living consistently with personal values.

2.7.4. Descriptive variables—To characterize the sample, we assess standard demographics and medical factors. Self-reported medical comorbidities are assessed via a checklist of nine chronic health conditions [43]. Functional status is measured with the 1-item Patient Generated Subjective Global Assessment (PG-SGA), a patient-reported version of the ECOG score [27]. Cancer information, such as time since diagnosis and treatments, is assessed via chart review. Additionally, seven self-report items assess physical and mental healthcare use, including outpatient and emergency room visits, use of alternative healthcare services, and (at baseline only) prior mindfulness training [43, 44]. Patients also report their prescribed and over-the-counter medications. Finally, measures of symptom severity are administered. Fatigue severity and frequency are measured with six items from the FSI [24, 25], and sleep disturbance, cognitive concerns, anxiety, and depressive symptoms are each assessed with a 6-item PROMIS measure [33, 36, 37, 45–47]. Pain is assessed with 3-item

and 4-item PROMIS measures of severity and interference, respectively [45, 48]. The extent to which hot flashes interfere with aspects of quality of life is evaluated with the 10-item Hot Flash Related Daily Interference Scale [49].

3. Statistical Analyses

3.1. Preliminary analyses

Distributional issues.—Univariate and descriptive analyses will be performed on all dependent variables, and if necessary, normalizing and/or variance stabilizing transformations will be applied to the data before inferential analyses are undertaken.

Missing data/attrition. We anticipate some missing data due to participant death, medical factors, and other reasons. For individuals who complete the first assessment but withdraw from the study, we will examine demographic, medical, and symptom factors that might be predictive of dropout using logistic regression. In the analyses for Aims 1 and 2 described below, all randomized participants will be included in intent-to-treat analyses [50], as the aims are concerned with the impact of the intervention on outcomes regardless of study completion status. Second, for participants who miss assessments, it is possible that attrition may be related to the study condition to which they have been assigned. We plan to use the random effects pattern-mixture model proposed by Hedeker and Gibbons [51] to address missing data. *Analyses of potential covariates.* Because patients will be randomly assigned to study conditions, significant differences in baseline values of all measured variables are not expected. Even so, we will assess for differences in baseline factors (e.g., demographic, medical and healthcare use variables, symptom levels) between study conditions [52]. Any differences will be taken into account when interpreting results, and factors that differ between the groups will be included as covariates in sensitivity analyses.

3.2. Analysis for aim 1

A linear mixed-model repeated measures approach will be used to test the hypothesis that ACT will improve fatigue interference as compared to the education/support condition. The model will include the main effect of time (as categorical) and study group (ACT vs. education/support) and the time-by-study group interaction. A treatment effect will be evidenced by a significant interaction between time and study group. If the treatment effect is significant, follow-up tests will be conducted to examine group differences at each follow-up, controlling for the outcome at baseline.

Our sample size is calculated based on the estimated difference between study conditions (ACT vs. education/support) on the primary outcome of fatigue interference at 2 weeks post-intervention. In our pilot study, we found a moderate effect ($d = -.30$) of study condition on fatigue interference at 1 month post-intervention [23]. It should be noted that only about half of the pilot sample had elevated fatigue interference at baseline (unlike the present study, the pilot study did not require all eligible patients to have clinically significant levels of fatigue interference); thus, the effect size is likely to be higher in the present study where the sample will have uniformly elevated fatigue interference at study entry. Indeed, among patients with moderate to severe baseline fatigue interference in our pilot study, we found a strong effect ($d = -.59$) of study condition on fatigue interference at 1 month post-intervention. Thus, we

conservatively estimate a medium effect size of $d = -.40$ at 2 weeks post-intervention. With a sample size of 198 patients at 2 weeks post-intervention (assuming 21% attrition based on our pilot [23]), we will have 80% power ($p = .05$, two-tailed) to detect a Cohen's d of $-.40$ in a linear mixed model [53]. At the final, 6-month follow-up with a sample size of 163 (assuming 35% attrition), we will have 80% power ($p = .05$, two-tailed) to detect a Cohen's d of $-.44$ [53]. The estimated attrition is based on our promising feasibility data for telephone-based ACT [23], use of telephone assessments to maximize compliance, and MBC survival rates [54].

We will use established minimal clinically important differences (MCIDs) on the FACT-G total score and subscale scores as anchors for determining a MCID in fatigue interference. MCIDs for MBC and other cancer patients are 2-point differences on the FACT-G subscale scores and a 5-point difference on the FACT-G total score, which fall in the range of .3 to .5 SDs [55, 56]. We will calculate mean changes in fatigue interference from baseline to 2 weeks post-intervention corresponding with established MCIDs on the FACT-G. Then effect sizes for these mean changes will be computed. Although MCIDs have yet to be determined for measures of fatigue interference, guidelines on MCIDs for pain interference and quality-of-life measures suggest that an effect size of .5 (.5 SD) is clinically meaningful [57–60]. The current trial is powered to detect this effect size.

3.3. Analysis for aim 2

Linear mixed models will be run to test the hypothesis that ACT will improve the secondary outcomes of sleep interference, engagement in daily activities, and quality of life as compared to the education/support condition. Each model will include the main effect of time (as categorical) and study group and the time-by-study group interaction. A treatment effect will be evidenced by a significant interaction between time and study group. The Sidak adjustment for correlated multiple outcomes will be used to control the familywise Type I error rate. If treatment effects are significant, follow-up tests will be conducted to examine group differences at each follow-up, controlling for the outcome at baseline.

3.4. Analysis for aim 3

The PROCESS macro developed by Andrew Hayes [61] will be used to test the hypothesis that increased psychological flexibility will mediate the effect of ACT on fatigue interference. The macro employs ordinary least squares regression. Bootstrapped confidence intervals will be computed for the indirect effect of study group on fatigue interference at 2 weeks post-intervention (via change in psychological flexibility over the same time period). Each analysis will control for baseline levels of the mediator and outcome. We tested for mediation at 2 weeks because this is the primary endpoint.

3.5. Analysis for aim 4

The PROCESS macro [61] will be used to explore the extent to which changes in mindfulness/acceptance and commitment/behavior change processes mediate (uniquely and collectively) the effect of ACT on fatigue interference. Both potential mediators will be entered into the same model. Bootstrapped confidence intervals will be computed for the indirect effect of study group on fatigue interference at 2 weeks post-intervention (via

change in mindfulness/acceptance and commitment/behavior change processes over the same time period). The analysis will control for baseline levels of the mediators and outcome.

3.6. Exploratory analyses

To inform future research, we will explore the extent to which sociodemographics (e.g., age, education) and clinical characteristics (e.g., cancer treatments, baseline severity of fatigue and other symptoms, healthcare use) moderate the effects of ACT on primary and secondary outcomes. For these analyses, we will use linear mixed modeling at a two-sided significance level of 0.05. Preliminary findings or hypotheses generated from these moderation analyses will be further tested in a future trial.

4. Discussion

The current trial addresses the top-rated concern of MBC patients—fatigue interference with activities, mood, and cognition [1, 3]. Fatigue has a substantial negative impact on their daily activities [1, 5]. Evidence-based interventions for fatigue interference are lacking. The ACT model [15] and our pilot data [23] provide strong justification for the current trial. In our pilot RCT, telephone-based ACT was highly feasible and acceptable to MBC patients and had a moderate effect on fatigue interference relative to an education/support condition; an even larger effect was observed in the subsample with elevated baseline fatigue interference [23]. To our knowledge, there is only one published large-scale trial of ACT in cancer, which focused on health behavior change in colorectal cancer survivors [62].

ACT is well-suited to address fatigue interference in cancer patients, as it emphasizes acceptance of the present moment (mindfulness), including internal experiences such as fatigue, and engagement in activities consistent with personal values [12]. The use of a fatigue interference inclusion criterion allows us to target those most in need of intervention—an approach rarely used in the broader literature on behavioral interventions for fatigue [63]. Another noteworthy feature of this trial is that it tests theory-driven mediators of ACT's effects. Only 3% of psychosocial intervention trials in cancer have analyzed potential mediators of intervention effects [64]. According to the ACT model, increased psychological flexibility is the primary mechanism underlying the beneficial health effects of ACT [15]. The core components of psychological flexibility are mindfulness/acceptance processes and commitment/behavior change processes. In prior studies with adults, psychological flexibility mediated the effects of ACT on mental health outcomes [65, 66]. If increases in overall psychological flexibility mediate ACT's effect on fatigue interference, then this finding would support a key aspect of the ACT model [15].

Additionally, we will explore whether change in the aforementioned core components of psychological flexibility mediate ACT's effect on fatigue interference. If our analysis shows that one component is driving ACT's effect, then the intervention could be modified in future trials to focus on this mechanism. For example, if commitment/behavior change processes more strongly mediate ACT's effect than does mindfulness/acceptance, this would provide a rationale for emphasizing these processes in future trials.

Our ability to demonstrate ACT's efficacy will lead to dissemination of this intervention to clinicians serving MBC patients, thereby addressing a critical gap in the evidence-based care of this rapidly growing population. This trial will also lay the groundwork for further application and testing of ACT on different functional outcomes and with a wide range of cancer populations.

Acknowledgements:

We thank the medical staff at study sites, Kelly Chinh, M.S., Isabella Stuart, B.S., Linda Brown, Ph.D., Erin Sadler, Ph.D., and Ekin Secinti, M.S. for their assistance with this project.

Funding: This work was supported by the National Cancer Institute [R01CA230542]. Ellen Krueger's work was also supported by the National Cancer Institute [T32CA117865]. The National Cancer Institute was not involved in the study design, the writing of the report, or the decision to submit the article for publication.

References

1. Cleeland CS, Mayer M, Dreyer NA, et al., Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. *The Breast*, 2014 23(6): 763–769. [PubMed: 25193423]
2. Aranda S, Schofield P, Weih L, et al., Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. *Eur J Cancer Care (Engl)*, 2005 14(3): 211–22. [PubMed: 15952965]
3. Butt Z, Rosenbloom SK, Abernethy AP, et al., Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. *J Natl Compr Canc Netw*, 2008 6(5): 448–55. [PubMed: 18492460]
4. Mosher CE and Duhamel KN, An examination of distress, sleep, and fatigue in metastatic breast cancer patients. *Psychooncology*, 2012 21: 100–107. [PubMed: 21105175]
5. Mosher CE, Tometich DB, Hirsh A, et al., Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility. *Psychooncology*, 2017 26(11): 1944–1951. [PubMed: 27648927]
6. Low CA and Stanton AL, Activity disruption and depressive symptoms in women living with metastatic breast cancer. *Health Psychol*, 2015 34(1): 89–92. [PubMed: 24447191]
7. Mucke M, Cuhls H, Peuckmann-Post V, Minton O, Stone P, and Radbruch L, Pharmacological treatments for fatigue associated with palliative care. *Cochrane Database Syst Rev*, 2015(5): CD006788. [PubMed: 26026155]
8. Mustafa M, Carson-Stevens S, Gillespie D, and Edwards AGK, Psychological interventions for women with metastatic breast cancer (Review). *Cochrane Database Syst Rev*, 2013(6): CD004253. [PubMed: 23737397]
9. Beatty L, Kemp E, Butow P, et al., A systematic review of psychotherapeutic interventions for women with metastatic breast cancer: Context matters. *Psychooncology*, 2018 27(1): 34–42. [PubMed: 28432855]
10. Spiegel D, Bloom JR, and Yalom I, Group support for patients with metastatic cancer: A randomized prospective outcome study. *Arch Gen Psychiatry*, 1981 38(5): 527–533. [PubMed: 7235853]
11. Bordeleau L, Szalai JP, Ennis M, et al., Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: Overall effects of the intervention and an exploration of missing data. *J Clin Oncol*, 2003 21(10): 1944–1951. [PubMed: 12743147]
12. Hayes SC, Strosahl KD, and Wilson KG, Acceptance and Commitment Therapy, second edition: The process and practice of mindful change. 2012, New York: Guilford Press.
13. Hulbert-Williams NJ, Storey L, and Wilson KG, Psychological interventions for patients with cancer: psychological flexibility and the potential utility of Acceptance and Commitment Therapy. *Eur J Cancer Care (Engl)*, 2015 24(1): 15–27. [PubMed: 25100576]

14. Feros DL, Lane L, Ciarrochi J, and Blackledge JT, Acceptance and Commitment Therapy (ACT) for improving the lives of cancer patients: a preliminary study. *Psychooncology*, 2013 22(2): 459–464. [PubMed: 23382134]
15. Hayes SC, Levin ME, Plumb-Villardaga J, Villatte JL, and Pistorello J, Acceptance and Commitment Therapy and contextual behavioral science: examining the progress of a distinctive model of behavioral and cognitive therapy. *Behav Ther*, 2013 44(2): 180–98. [PubMed: 23611068]
16. Buhrman M, Skoglund A, Husell J, et al., Guided internet-delivered acceptance and commitment therapy for chronic pain patients: A randomized controlled trial. *Behav Res Ther*, 2013 51(6): 307–315. [PubMed: 23548250]
17. Hann KEJ and McCracken LM, A systematic review of randomized controlled trials of Acceptance and Commitment Therapy for adults with chronic pain: Outcome domains, design quality, and efficacy. *J Contextual Behav Sci*, 2014 3(4): 217–227.
18. Hughes LS, Clark J, Colclough JA, Dale E, and McMillan D, Acceptance and Commitment Therapy (ACT) for chronic pain: A systematic review and meta-analyses. *Clin J Pain*, 2017 33(6): 552–568. [PubMed: 27479642]
19. Wetherell JL, Afari N, Rutledge T, et al., A randomized, controlled trial of acceptance and commitment therapy and cognitive-behavioral therapy for chronic pain. *Pain*, 2011 152(9): 2098–2107. [PubMed: 21683527]
20. Rost AD, Wilson K, Buchanan E, Hildebrandt MJ, and Mutch D, Improving psychological adjustment among late-stage ovarian cancer patients: Examining the role of avoidance in treatment. *Cogn Behav Pract*, 2012 19(4): 508–517.
21. Arch JJ, Fishbein JN, Ferris MC, et al., Acceptability, feasibility, and efficacy potential of a multimodal acceptance and commitment therapy intervention to address psychosocial and advance care planning needs among anxious and depressed adults with metastatic cancer. *J Palliat Med*, in press.
22. Mohabbat-Bahar S, Maleki-Rizi F, Akbari ME, and Moradi-Joo M, Effectiveness of group training based on Acceptance and Commitment Therapy on anxiety and depression of women with breast cancer. *Iran J Cancer Prev*, 2015 8(2): 71–76. [PubMed: 25960844]
23. Mosher CE, Secinti E, Li R, et al., Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial. *Support Care Cancer*, 2018 26(6): 1993–2004. [PubMed: 29327085]
24. Hann DM, Denniston MM, and Baker F, Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. *Qual Life Res*, 2000 9(7): 847–54. [PubMed: 11297027]
25. Hann DM, Jacobsen PB, Azzarello LM, et al., Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory. *Qual Life Res*, 1998 7(4): 301–310. [PubMed: 9610214]
26. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, and Hendrie HC, Six-item screener to identify cognitive impairment among potential subjects for clinical research. *Med Care*, 2002 40(9): 771–81. [PubMed: 12218768]
27. Bauer J, Capra S, and Ferguson M, Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. *Eur J Clin Nutr*, 2002 56(8): 779–85. [PubMed: 12122555]
28. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, and Senkus E, Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2012 23(suppl. 7): vii11–vii19. [PubMed: 22997442]
29. Snow G, blockrand: Randomization for block random clinical trials. R package v 13 2013.
30. Team, R.C., R: A language and environment for statistical computing. 2014, Vienna, Austria: R Foundation for Statistical Computing.
31. A-Tjak JGL, Davis ML, Morina N, Powers MB, Smits JAJ, and Emmelkamp PMG, A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. *Psychother Psychosom*, 2015 84: 30–36. [PubMed: 25547522]

32. Johns SA, Stutz PV, Talib TL, et al., Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial. *Cancer*, 2020 126(1): 211–218. [PubMed: 31539169]
33. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, and Cella D, Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS(R)): depression, anxiety, and anger. *Assessment*, 2011 18(3): 263–83. [PubMed: 21697139]
34. Moshier CE, Winger JG, Hanna N, et al., Randomized pilot trial of a telephone symptom management intervention for symptomatic lung cancer patients and their family caregivers. *J Pain Symptom Manage*, 2016 52(4): 469–482. [PubMed: 27401514]
35. Porter LS, Keefe FJ, Baucom DH, et al., Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial. *Cancer*, 2009 115(18 Suppl): 4326–38. [PubMed: 19731357]
36. Yu L, Buysse DJ, Germain A, et al., Development of short forms from the PROMIS sleep disturbance and sleep-related impairment item banks. *Behav Sleep Med*, 2012 10(1): 6–24.
37. Buysse DJ, Yu L, Moul DE, et al., Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. *Sleep*, 2010 33(6): 781–792. [PubMed: 20550019]
38. Hahn EA, DeVellis RF, Bode RK, et al., Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. *Qual Life Res*, 2010 19(7): 1035–1044. [PubMed: 20419503]
39. Cella DF, Tulsky DS, Gray G, et al., The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol*, 1993 11(3): 570–579. [PubMed: 8445433]
40. Bond FW, Hayes SC, Baer RA, et al., Preliminary psychometric properties of the Acceptance and Action Questionnaire–II: A revised measure of psychological inflexibility and experiential avoidance. *Behav Ther*, 2011 42(4): 676–688. [PubMed: 22035996]
41. Feldman G, Hayes A, Kumar S, Greeson J, and Laurenceau J-P, Mindfulness and emotion regulation: The development and initial validation of the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R). *J Psychopathol Behav Assess*, 2007 29(3): 177–190.
42. Smout M, Davies M, Burns N, and Christie A, Development of the Valuing Questionnaire (VQ). *J Contextual Behav Sci*, 2014 3(3): 164–172.
43. Kroenke K, Theobald D, Norton K, et al., The Indiana Cancer Pain and Depression (INCPAD) trial: Design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. *Gen Hosp Psychiatry*, 2009 31(3): 240–53. [PubMed: 19410103]
44. Kroenke K, Bair M, Damush T, et al., Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study: design and practical implications of an intervention for comorbid pain and depression. *Gen Hosp Psychiatry*, 2007 29(6): 506–17. [PubMed: 18022044]
45. Cella D, Riley W, Stone A, et al., The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *J Clin Epidemiol*, 2010 63(11): 1179–94. [PubMed: 20685078]
46. Jensen RE, Potosky AL, Moinpour CM, et al., United States population-based estimates of Patient-Reported Outcomes Measurement Information System symptom and functional status reference values for individuals with cancer. *J Clin Oncol*, 2017 35(17): 1913–1920. [PubMed: 28426375]
47. Choi SW, Reise SP, Pilkonis PA, Hays RD, and Cella D, Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. *Qual Life Res*, 2010 19(1): 125–136. [PubMed: 19941077]
48. Amtmann D, Cook KF, Jensen MP, et al., Development of a PROMIS item bank to measure pain interference. *Pain*, 2010 150(1): 173–182. [PubMed: 20554116]
49. Carpenter JS, The Hot Flash Related Daily Interference Scale: A tool for assessing the impact of hot flashes on quality of life following breast cancer. *J Pain Symptom Manage*, 2001 22(6): 979–989. [PubMed: 11738160]

50. Lachin JM, Statistical considerations in the intent-to-treat principle. *Control Clin Trials*, 2000 21(3): 167–189. [PubMed: 10822117]
51. Hedeker D and Gibbons RD, MIXOR: a computer program for mixed-effects ordinal regression analysis. *Comput Methods Programs Biomed*, 1996 49(2): 157–76. [PubMed: 8735023]
52. Altman DG, Comparability of randomised groups. *J R Stat Soc Series D Statistician* 1985 34(1): 125–136.
53. Dong N and Maynard R, PowerUp!: A tool for calculating minimum detectable effect sizes and minimum required sample sizes for experimental and quasi-experimental design studies. *J Res Educ Eff*, 2013 6(1): 24–67.
54. American Cancer Society, Breast Cancer Facts and Figures 2017–2018. 2017, Atlanta: American Cancer Society.
55. Yost KJ and Eton DT, Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. *Eval Health Prof*, 2005 28(2): 172–191. [PubMed: 15851772]
56. Eton DT, Cella D, Yost KJ, et al., A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. *J Clin Epidemiol*, 2004 57(9): 898–910. [PubMed: 15504633]
57. Dworkin RH, Turk DC, Wyrwich KW, et al., Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*, 2008 9(2): 105–121. [PubMed: 18055266]
58. Sloan J, Symonds T, Vargas-Chanes D, and Fridley B, Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. *Drug Inf J*, 2003 37(1): 23–31.
59. Sloan JA, Frost MH, Berzon R, et al., The clinical significance of quality of life assessments in oncology: a summary for clinicians. *Support Care Cancer*, 2006 14(10): 988–998. [PubMed: 16794811]
60. Norman GR, Sloan JA, and Wyrwich KW, Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. *Med Care*, 2003 41(5): 582–92. [PubMed: 12719681]
61. Hayes AF, Introduction to mediation, moderation, and conditional process analysis: A regression-based approach. 2013, New York: Guilford Press.
62. Hawkes AL, Chambers SK, Pakenham KI, et al., Effects of a telephone-delivered multiple health behavior change intervention (CanChange) on health and behavioral outcomes in survivors of colorectal cancer: a randomized controlled trial. *J Clin Oncol*, 2013 31(18): 2313–21. [PubMed: 23690410]
63. Bower JE, Treating cancer-related fatigue: The search for interventions that target those most in need. *J Clin Oncol*, 2012 30(36): 4449–4450. [PubMed: 23109702]
64. Stanton AL, Luecken LJ, MacKinnon DP, and Thompson EH, Mechanisms in psychosocial interventions for adults living with cancer: Opportunity for integration of theory, research, and practice. *J Consult Clin Psychol*, 2013 81(2): 318–335. [PubMed: 22663900]
65. Bohlmeijer ET, Fledderus M, Rokx TAJJ, and Pieterse ME, Efficacy of an early intervention based on acceptance and commitment therapy for adults with depressive symptomatology: Evaluation in a randomized controlled trial. *Behav Res Ther*, 2011 49(1): 62–67. [PubMed: 21074752]
66. Fledderus M, Bohlmeijer ET, Smit F, and Westerhof GJ, Mental health promotion as a new goal in public mental health care: A randomized controlled trial of an intervention enhancing psychological flexibility. *Am J Public Health*, 2010 100(12): 2372. [PubMed: 20966360]

Figure 1. Conceptual Model

Note. Although psychological flexibility is a secondary outcome rather than a mediator in this pilot trial, our analyses will set the stage for formal mediation analyses in a future large-scale trial.

Table 1:**Summary of Core Components of Each Intervention Condition**

Acceptance and Commitment Therapy	Education/Support
<ul style="list-style-type: none"> • Identify current attempts to control fatigue and their impact on quality of life • Practice mindfulness with the therapist during sessions and at home (e.g., awareness of the breath, body scan, noticing sounds). • Practice cognitive defusion—learning to notice thoughts, feelings, and symptoms rather than being overwhelmed by them (e.g., passengers on the bus metaphor) • Observe and detach from fatigue and related thoughts and emotions to cultivate a transcendent sense of self from which to observe and accept changing experience. Willingness to experience the present moment with courage and flexibility is emphasized. • Identify key values (e.g., being a loving partner, giving to one's community) • Goal setting and practice of value-based actions 	<ul style="list-style-type: none"> • Orient patient to the medical center and treatment team; overview of quality of life concerns and discussion of physical quality of life and symptoms • Discuss common social challenges (e.g., talking with children about cancer and employment issues); tips on managing household challenges when ill; referral to resources for addressing social challenges • Discuss common emotional responses to cancer, including anxiety and depressive symptoms, and cognitive changes following cancer treatment; referral to mental health services • Describe common financial concerns related to cancer and its treatment; referral to resources for addressing financial challenges • Methods of evaluating health information on the Internet and other modalities • Review of prior session topics and referral to websites with cancer-related information

Table 2:**Measures and Timing of Data Collection**

Domain	Measure	Baseline	2-weeks post-intervention	3-months post-intervention	6-months post-intervention
<i>Primary outcome:</i>					
Fatigue interference	Fatigue interference subscale of FSI	✓	✓	✓	✓
<i>Secondary outcomes:</i>					
Sleep interference	PROMIS short-form sleep-related impairment measure	✓	✓	✓	✓
Engagement in daily activities	PROMIS short-form measure of ability to participate in social roles and activities	✓	✓	✓	✓
Quality of life	FACT-G	✓	✓	✓	✓
<i>Hypothesized mediator:</i>					
Psychological flexibility	Acceptance and Action Questionnaire-II	✓	✓	✓	✓
<i>Exploratory mediators:</i>					
Mindfulness/Acceptance	Cognitive and Affective Mindfulness Scale-Revised	✓	✓	✓	✓
Commitment/Behavior change	Values Progress subscale of Valuing Questionnaire	✓	✓	✓	✓
<i>Demographic and medical factors:</i>					
Sociodemographics	Sociodemographics	✓			
Medical comorbidity	Checklist of 9 conditions	✓			
Functional status	Patient-reported ECOG	✓	✓	✓	✓
Cancer information (e.g., date of diagnosis, cancer treatments)	Chart review	✓	✓	✓	✓
Physical and mental healthcare use	Healthcare use interview	✓	✓	✓	✓
Medications	Medication interview	✓	✓	✓	✓
<i>Severity of symptoms:</i>					
Fatigue severity, sleep disturbance, cognitive concerns, anxiety, depressive symptoms, pain severity and interference, and hot flash interference	Fatigue severity and frequency items from FSI; PROMIS short-form measures of sleep disturbance, cognitive concerns, anxiety, depression, and pain severity and interference; Hot Flash Related Daily Interference Scale	✓	✓	✓	✓

Note. FSI = Fatigue Symptom Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System; FACT-G = Functional Assessment of Cancer Therapy-General; ECOG = Eastern Cooperative Oncology Group.